ArticleClinical and experimental medicine2011
Survivin -31C/G polymorphism and gastric cancer risk in a Brazilian population.
Article in Clinical and experimental medicine, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 8 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 8 syntheses or guidelines pooled it, 34 citations in OpenAlex.
- Survivin (BIRC5) Gene Polymorphism (rs9904341) Is Associated with Cancer Risk: A Meta-Analysis.Asian Pacific journal of cancer prevention : APJCP · 2025Pooled it
- Survivin rs9904341 polymorphism significantly increased the risk of cancer: evidence from an updated meta-analysis of case-control studies.International journal of clinical oncology · 2019Pooled it
- Survivin rs9904341 (G>C) polymorphism contributes to cancer risk: an updated meta-analysis of 26 studies.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2014Pooled it
- Association between survivin -31G>C polymorphism and cancer risk: meta-analysis of 29 studies.Journal of cancer research and clinical oncology · 2014Pooled it
- Pooled it
- Survivin -31G>C polymorphism and gastrointestinal tract cancer risk: a meta-analysis.PloS one · 2013Pooled it
- Association between survivin -31G > C promoter polymorphism and cancer risk: a meta-analysis.European journal of human genetics : EJHG · 2012Pooled it
- Survivin promoter -31G/C (rs9904341) polymorphism and cancer susceptibility: a meta-analysis.Molecular biology reports · 2012Pooled it
- Survivin Promoter Polymorphism (-31 C/G): A Genetic Risk Factor for Oral CancerAsian Pacific journal of cancer prevention : APJCP · 2019Article
- Survivin expression in canine spontaneous cutaneous and subcutaneous tumors and its prognostic importance.Veterinary world · 2017Article
- The anti-apoptotic protein survivin can improve the prognostication of meningioma patients.PloS one · 2017Article
- Survivin: A molecular biomarker in cancer.The Indian journal of medical research · 2015Review
- Apoptotic mediators in patients with severe and non-severe dengue from Brazil.Journal of medical virology · 2014Article
- Role of gene polymorphisms in gastric cancer and its precursor lesions: current knowledge and perspectives in Latin American countries.World journal of gastroenterology · 2014Review
- Analysis of the methylation patterns of the p16 INK4A, p15 INK4B, and APC genes in gastric adenocarcinoma patients from a Brazilian population.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2013Article
- Influence of survivin (BIRC5) and caspase-9 (CASP9) functional polymorphisms in renal cell carcinoma development: a study in a southern European population.Molecular biology reports · 2013Article
- Functional promoter -31G/C variant of Survivin gene predict prostate cancer susceptibility among Chinese: a case control study.BMC cancer · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Gastric cancer, despite its decline in incidence, remains a public health problem worldwide, especially in Brazil, where higher incidence indexes are still described. The Survivin gene codifies a multifunctional protein involved in the regulation of the cell cycle and inhibition of the apoptotic pathway, and a polymorphism (-31C/G) located in its promoter region is associated with gene regulation. In order to evaluate the correlation of this polymorphism with gastric cancer risk in a northern Brazil population, we sequenced a fragment containing the polymorphism in individuals with gastric cancer and controls. We observed no differences of alleles and genotype frequencies between cases and controls. However, G carriers of the tumor group had an increased relative risk of developing tumors of diffuse type (OR: 2.22-IC 95%: 0.4835-10.2137), localized in the antrum (OR: 2.16-IC 95%: 0.4811-9.6971) and in younger patients (<50 years-old) (OR: 3.65-IC 95%: 0.4012-33.2429), although with no statistical significance. Nevertheless, C carriers with a high D17S250 microsatellite instability (TP53 gene) show a higher risk to develop gastric tumors (P = 0.0453; OR: 4.1556-IC95%: 0.9716-17.7728), suggesting that the mutate TP53 gene may fail in control and inhibition of Survivin expression, favoring the gastric carcinogenesis. The present result suggests that the presence of the C allele of -31C/G Survivin promoter polymorphism in combination with D17S250 instability may be used as a risk factor for gastric cancer in our population. However, other studies based on a larger sample size are required to properly assess such hypothesis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.